原发灶放疗与新发转移性乳腺癌总生存:回顾性多中心队列分析
该回顾性多中心队列纳入2008—2014年1965例诊断后至少1年仍无进展且存活的新发转移性乳腺癌(dnMBC)患者,比较单纯放疗(ERT)、单纯手术、手术联合放疗(BMT)与未行局部区域治疗(no-LRT)的生存结局。校正主要预后因素后,ERT与BMT组总生存(OS)显著优于no-LRT组,单纯手术组无显著差异;倾向评分匹配后结果相似,三种局部治疗均与更好的无进展生存(PFS)相关。
要点
- 校正主要预后因素后,ERT组OS显著优于no-LRT组(HR=0.63,95%CI 0.49–0.80,p<0.001)。
- BMT组OS同样显著优于no-LRT组(HR=0.61,95%CI 0.47–0.78,p<0.001),幅度与ERT相近。
- 单纯手术组OS与no-LRT组无显著差异(HR=0.87,95%CI 0.61–1.26,p=0.466)。
核心结论
- 在新发转移性乳腺癌中,单纯放疗与手术联合放疗均与更好的总生存相关,单纯手术未见显著OS获益;观察性设计无法排除选择偏倚。
研究设计与样本
- 回顾性多中心真实世界队列分析,2008—2014年共识别4507例dnMBC患者。
- 仅纳入诊断后至少1年仍存活且系统治疗下无进展者,最终分析n=1965。
- 采用倾向评分匹配进行敏感性分析。
主要发现
- 891/1965例(45%)接受局部区域治疗:ERT 366例(41.1%)、单纯手术122例(13.7%)、BMT 403例(45.2%)。
- 校正主要预后因素后,ERT组OS较no-LRT组显著延长(HR=0.63,95%CI 0.49–0.80,p<0.001)。
- BMT组OS较no-LRT组显著延长(HR=0.61,95%CI 0.47–0.78,p<0.001)。
- 单纯手术组OS与no-LRT组无显著差异(HR=0.87,95%CI 0.61–1.26,p=0.466)。
- 多因素分析中ERT、手术和BMT均与显著更好的PFS相关。
临床怎么用
- 对系统治疗后至少1年无进展的dnMBC患者,原发灶单纯放疗可作为与手术联合放疗相当的局部治疗选项加以考虑。
- 单纯手术不宜作为唯一局部治疗方式用于追求生存获益。
- 治疗决策需结合选择偏倚风险个体化判断,不能直接外推为因果结论。
局限性
- 为观察性研究,即使校正已知预后因素并使用倾向评分分析,选择偏倚仍不能消除。
- 仅纳入诊断后至少1年存活且无进展的患者,存在选择与 immortal time 偏倚可能。
- 缺少随机对照证据支持因果关系。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The impact of locoregional treatment (LRT) on overall survival (OS) in de novo metastatic breast cancer (dnMBC) is still under debate, with very few data available regarding exclusive radiotherapy (ERT) as a therapeutic modality. METHODS: We evaluated the impact of ERT, exclusive surgery, or a combination of surgery plus radiotherapy (bimodality therapy, BMT) on survival outcomes in a national real-life dnMBC cohort. The primary and secondary end points were OS and progression free survival (PFS) according to LRT (ERT, exclusive surgery, BMT) and no LRT. Sensitivity analyses were performed using propensity score matched analyses. RESULTS: From 2008 to 2014, 4507 dnMBC patients were identified. Only patients alive and free from progression under systemic therapy at least 1 year after diagnosis were included (n = 1965). Forty-five percent of patients (891/1965) underwent LRT: 41.1% (n = 366) ERT, 13.7% (n = 122) exclusive surgery, and 45.2% (n = 403) BMT. OS adjusted for major prognostic factors was significantly longer in the ERT and BMT group compared with no-LRT group, but not exclusive surgery (hazard ratio (HR) = 0.63, 95% confidence interval (CI) [0.49, 0.80], p < 0.001, HR = 0.61, 95%CI [0.47, 0.78], p < 0.001 and HR = 0.87, 95%CI [0.61, 1.26], p = 0.466 respectively). Results were similar after matching on a propensity score. ERT, surgery and BMT were all associated with a significantly better PFS in multivariable analysis. CONCLUSION: ERT was significantly associated with better OS in dnMBC, in the same magnitude as BMT, compared with no-LRT. However, even with statistical models adjusted for known prognostic factors and propensity score analysis, selection biases cannot be eliminated from observational studies.
引用
- Pons-Tostivint E, Kirova Y, Lusque A, et al. Radiation therapy to the primary tumor for de novo metastatic breast cancer and overall survival in a retrospective multicenter cohort analysis. Radiother Oncol. 2020. PMID: 31931289. doi:10.1016/j.radonc.2019.12.019
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。